Thus, we propose that the DPP4 inhibitor, sitagliptin, and miR-23b-3p represent candidate therapeutics that may be used individually or in combination to alleviate pulmonary fibrosis in patients with ARDS. Here, DPP4 is linked to pulmonary fibrosis.